{"paper_id":"4bad8974-1945-4d80-bac6-317ca2660c59","body_text":"Abstract\nPurpose\nTo quantify the mRNA levels of MMP-3, MMP-9, VEGF and Survivin in peripheral blood and the serum levels of CA-125 and Ca19-9 in women with and without endometriosis and to investigate the performance of these markers to differentiate between deep and ovarian endometriosis.\nMethods\nA case control study enrolled a series of 60 patients. Twenty controls have been matched with 20 cases of ovarian and 20 cases of deep endometriosis. Univariable and multivariable performance of serum CA125 and CA19-9, mRNA for Survivin, MMP9, MMP3 and VEGF genes have been evaluated by means of ROC curves and logistic regression, respectively.\nResults\nNo difference in markers’ concentration was detected between ovarian and deep endometriosis. In comparison with controls, serum CA125 and CA19 yielded the better sensitivity followed by mRNA for Survivin gene (81.5, 51.9 and 7.5% at 10% false positive rate, respectively). Multivariable estimated odds of endometriosis yielded a sensitivity of 87% at the same false positive rate.\nConclusions\nA combination of serum and molecular markers could allow a better diagnosis of endometriosis.\nSimilar content being viewed by others\nReferences\nMissmer SA, Cramer DW (2003) Epidemiology of endometriosis. Obstet Gynecol Clin North Am 30(1):1–19\nAmerican Society for Reproductive Medicine (1997) Revised classification of endometriosis. Fertil Steril 67:817–821\nChapron C, Fauconnier A, Vieira M et al (2003) Anatomical distribution of deeply infiltrating endometriosis: surgical implications and proposition for a classification. Hum Reprod 18(1):157–161\nRoyal College of Obstetrics and Gynaecology (2006) The investigation and management of endometriosis. Green-top guideline no 24. RCOG, London\nVercellini P, Fedele L, Aimi G, Pietropaolo G, Consonni D, Crosignani PG (2007) Association between endometriosis stage, lesion type, patient characteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients. Hum Reprod 22(1):266–271\nKoninckx PR, Martin D (1994) Treatment of deeply infiltrating endometriosis. Curr Opin Obstet Gynecol 6(3):231–241\nAbrao MS, Goncalves MO, Dias JA Jr, Podgaec S, Chamie LP, Blasbalg R (2007) Comparison between clinical examination, transvaginal sonography and magnetic resonance imaging for the diagnosis of deep endometriosis. Hum Reprod 22(12):3092–3097\nChapron C, Chopin N, Borghese B, Malartic C, Decuypere F, Foulot H (2004) Surgical management of deeply infiltrating endometriosis: an update. Ann NY Acad Sci 1034:326–337\nAttaran M, Falcone T, Goldberg J (2002) Endometriosis: still tough to diagnose and treat. Clevel Clin J Med 69(8):647–653\nHarkki-Siren P, Sjoberg J, Kurki T (1999) Major complications of laparoscopy: a follow-up Finnish study. Obstet Gynecol 94:94–98\nChapron C, Querleu D, Bruhat MA et al (1998) Surgical complications of diagnostic and operative gynaecological laparoscopy: a series of 29, 966 cases. Hum Reprod 13:867–872\nOsteen KG, Yeaman GR, Bruner-Tran KL (2003) Matrix metalloproteinase and endometriosis. Semin Reprod Med 21:155–164\nUeda M, Yamashita Y, Takehara M et al (2002) Survivin gene expression in endometriosis. J Clin Endocrinol Metab 87(7):3452–3459\nRamon L, Gilabert-Estelles J, Castello R, Gilabert J, Espana F, Romeu A et al (2005) mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay. Hum Reprod 20:272–278\nBruner-tran KL, Eisenberg E, Yeaman GR, Anderson TA, McBean J, Osteen KG (2002) Steroid and cytokine regulation of matrix metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice. J Clin Endocrinol Metab 87:4782–4791\nMulayim N, Savlu A, Guzeloglu-Kayisli O, Kayisli UA, Arici A (2004) Regulation of endometrial-stromal cell matrix metalloproteinase activity and invasiveness by interleukin-8. Fertil Steril 81:904–911\nWu MH, Shoji Y, Wu MC et al (2005) Suppression of matrix metalloproteinase-9 by prostaglandin E2 in peritoneal macrophage is associated with severity of endometriosis. Am J Pathol 167:1061–1069\nGilabert-Estelle’s J, Ramo’n LA, Espan˜a F et al (2007) Expression of angiogenic factors in endometriosis: relationship to fibrinolytic and metalloproteinase systems. Hum Reprod 22:2120–2127\nEel-D Othman, Hornung D, Salem HT, Khalifa EA, El-Metwally TH, Al-Hendy A (2008) Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. Eur J Obstet Gynecol Reprod Biol Appl 137:240–246\nBourlev V, Volkov N, Pavlovitch S, Lets N, Larsson A, Olovsson M (2006) The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction 132:501–509\nTan XJ, Lang JH, Liu DY, Shen K, Leng JH, Zhu L (2002) Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis. Fertil Steril 78:148–153\nTakehara M, Ueda M, Yamashita Y, Terai Y, Hung YC, Ueki M (2004) Vascular endothelial growth factor A and C gene expression in endometriosis. Hum Pathol 35:1369–1375\nDi Carlo C, Bonifacio M, Tommaselli GA, Bifulco G, Guerra G, Nappi C (2009) Metalloproteinases, vascular endothelial growth factor and angiopoietin 1 and 2 in eutopic and ectopic endometrium. Fertil Steril 91:2315–2323\nMachado DE, Abrao MS, Berardo PT, Takiya CM, Nasciutti LE (2008) Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril 90:148–155\nHarada T, Kubota T, Aso T (2002) Usefulness of CA19–9 versus CA125 for the diagnosis of endometriosis. Fertil Steril 78:733–739\nMol BW, Bayram N, Lijmer JG et al (1998) The performance of CA-125 measurement in the detection of endometriosis: a meta-analysis. Fertil Steril 70:1101–1108\nSomigliana E, Vigano` P, Tirelli AS et al (2004) Use of the concomitant serum dosage of CA 125, CA 19–9 and interleukin-6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Hum Reprod 19(8):1871–1876\nKurdoglu Z, Gursoy R, Kurdoglu M, Erdem M, Erdem O, Erdem A (2009) Comparison of the clinical value of CA 19–9 versus CA 125 for the diagnosis of endometriosis. Fertil Steril 92(5):1761–1763\nOsteen KG, Bruner KL, Sharpe-Timms KL (1996) Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis. Semin Reprod Endocrinol 14:247–255\nSillem M, Prifti S, Koch A, Neher M, Jauckus J, Runnebaum B (2001) Regulation of matrix metalloproteinases and their inhibitors in uterine endometrial cells of patients with and without endometriosis. Eur J Obstet Gynecol Reprod Biol 95:167–174\nGilabert-Estelle’s J, Estelle’s A, Gilabert J et al (2003) Expression of several components of the plasminogen activator and matrix metalloproteinas systems in endometriosis. Hum Reprod 18:1516–1522\nChung HW, Wen Y, Chun SH, Nezhat C, Woo BH, Lake Polan M (2001) Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium in women with endometriosis: a rationale for endometriotic invasiveness. Fertil Steril 75:152–159\nLi Y, Lang JH (2006) Expressions of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 mRNA in endometriosis. Zhonghua Fu Chan Ke Za Zhi 41:30–33\nAmbrosini G, Adida C, Altieri DC (1999) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921\nKonno R, Yamakawa H, Utsunomiya H, Ito K, Sato S, Yajima A (2000) Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod 6:529–534\nFujino K, Ueda M, Takehara M et al (2006) Transcriptional expression of survivin and its splice variants in endometriosis. Mol Hum Reprod 12(6):383–388\nGagné D, Pagé M, Robitaille G, Hugo P, Gosselin D (2003) Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis. Hum Reprod 18:1674–1680\nMatalliotakis IM, Goumenou AG, Koumantakis GE et al (2003) Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines. Int Immunopharmacol 3:81–89\nOliveira VA, Abreu LG, Ferriani RA, Reis RM, Moura MD (2005) Vascular endothelial growth factor in the plasma, follicular fluid and granulosa cells of women with endometriosis submitted to in vitro fertilization–a pilot study. Gynecol Endocrinol 20:284–288\nXavier P, Belo L, Beires J, Rebelo I, Martinez-de-Oliveira J, Lunet N, Barros H (2006) Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet 273:227–231\nConflict of interest\nThe authors declare that they have no conflict of interest in this study.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nMabrouk, M., Elmakky, A., Caramelli, E. et al. Performance of peripheral (serum and molecular) blood markers for diagnosis of endometriosis. Arch Gynecol Obstet 285, 1307–1312 (2012). https://doi.org/10.1007/s00404-011-2122-4\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-011-2122-4","source_license":"public-domain-us","license_restricted":false}